UNC lab partnership develops first COVID-19 treatment approved by FDA
Posted Nov 7, 2020
Remdesivir, a drug developed through a partnership between UNC’s Baric Lab and Gilead Sciences, was recently approved as a COVID-19 treatment. As of Oct. 22, remdesivir is the first and only FDA-approved COVID-19 treatment in the U.S. UNC faculty and students reflected on the significance of remdesivir’s approval and what this means for the University.
(Daily Tar Heel)
Related: Campus Connections
UNC's Online MBA, nursing programs rank in top 10Online master’s programs from UNC-Chapel Hill’s Kenan-Flagler Business School and School of Nursing are among the best in the nation in the 2025 U.S. News...
Fri Jan 31, 2025William Leuchtenburg, UNC professor emeritus, eminent historian & Ken Burns consultant, dies at 102
William Leuchtenburg, a prize-winning historian widely admired for his authoritative writings on the U.S. presidency and as the reigning scholar on Franklin Roosevelt and the...
Thu Jan 30, 2025
Morehead Planetarium nominated in national contest
A planetarium in North Carolina has been nominated for Best Planetarium by USA Today’s Readers’ Choice 2025. Morehead Planetarium in Chapel Hill is currently in...
Wed Jan 29, 2025
Shrunken Head Boutique sees Bill Belichik hiring as a win for their business
Employees at The Shrunken Head say former NFL head coach and eight-time Super Bowl champion Bill Belichick will bring wins on the field and in...
Mon Jan 27, 2025
